靶向GPRC5D的CAR T细胞治疗骨髓瘤
这项1期剂量递增研究将靶向GPRC5D的CAR T细胞疗法MCARH109用于17例经重度预处理的多发性骨髓瘤患者(含BCMA CAR T后复发者),最大耐受剂量为150×10^6个CAR T细胞,全队列71%缓解,25×10^6至150×10^6剂量组58%缓解。
要点
- 最大耐受剂量为150×10^6个CAR T细胞。
- 450×10^6剂量组出现1例4级细胞因子释放综合征和ICANS、2例3级小脑疾病。
- 25×10^6至150×10^6剂量组12例中未出现小脑疾病、任何级别ICANS或≥3级细胞因子释放综合征。
核心结论
- 靶向GPRC5D的CAR T细胞疗法MCARH109的研究结果证实,GPRC5D是多发性骨髓瘤中一个活跃的免疫治疗靶点。
研究设计与样本
- 1期剂量递增研究,共入组17例经重度预处理的多发性骨髓瘤患者并接受MCARH109治疗,包括BCMA CAR T细胞治疗后复发的患者。
主要发现
- 最大耐受剂量确定为150×10^6个CAR T细胞。
- 450×10^6 CAR T细胞剂量组中,1例发生4级细胞因子释放综合征和免疫效应细胞相关神经毒性综合征(ICANS),2例发生原因不明的3级小脑疾病。
- 接受25×10^6至150×10^6个细胞剂量的12例患者中,未发生小脑疾病、任何级别ICANS或3级及以上细胞因子释放综合征。
- 全队列71%的患者报告缓解,接受25×10^6至150×10^6个细胞剂量的患者中58%缓解。
- 全队列中10例既往接受过BCMA治疗的患者有7例缓解,接受25×10^6至150×10^6个细胞剂量的6例此类患者有3例缓解。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapies have generated responses in patients with advanced myeloma, but relapses are common. G protein-coupled receptor, class C, group 5, member D (GPRC5D) has been identified as an immunotherapeutic target in multiple myeloma. Preclinical studies have shown the efficacy of GPRC5D-targeted CAR T cells, including activity in a BCMA antigen escape model. METHODS: In this phase 1 dose-escalation study, we administered a GPRC5D-targeted CAR T-cell therapy (MCARH109) at four dose levels to patients with heavily pretreated multiple myeloma, including patients with relapse after BCMA CAR T-cell therapy. RESULTS: A total of 17 patients were enrolled and received MCARH109 therapy. The maximum tolerated dose was identified at 150×106 CAR T cells. At the 450×106 CAR T-cell dose, 1 patient had grade 4 cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome (ICANS), and 2 patients had a grade 3 cerebellar disorder of unclear cause. No cerebellar disorder, ICANS of any grade, or cytokine release syndrome of grade 3 or higher occurred in the 12 patients who received doses of 25×106 to 150×106 cells. A response was reported in 71% of the patients in the entire cohort and in 58% of those who received doses of 25×106 to 150×106 cells. The patients who had a response included those who had received previous BCMA therapies; responses were observed in 7 of 10 such patients in the entire cohort and in 3 of 6 such patients who received 25×106 to 150×106 cells. CONCLUSIONS: The results of this study of a GPRC5D-targeted CAR T-cell therapy (MCARH109) confirm that GPRC5D is an active immunotherapeutic target in multiple myeloma. (Funded by Juno Therapeutics/Bristol Myers Squibb; ClinicalTrials.gov number, NCT04555551.).
引用
- Mailankody S, Devlin SM, Landa J, et al. GPRC5D-Targeted CAR T Cells for Myeloma. N Engl J Med. 2022. PMID: 36170501. doi:10.1056/NEJMoa2209900
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。